These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24696869)

  • 1. An update on intravitreal implants in use for eye disorders.
    Lambiase A; Abdolrahimzadeh S; Recupero SM
    Drugs Today (Barc); 2014 Mar; 50(3):239-49. PubMed ID: 24696869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
    Arcinue CA; Cerón OM; Foster CS
    J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
    Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular corticosteroids for posterior segment disease: 2012 update.
    Kiernan DF; Mieler WF
    Expert Opin Pharmacother; 2012 Aug; 13(12):1679-94. PubMed ID: 22783878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of steroids into the eye for the treatment of macular edema.
    Hadayer A; Schaal S
    Expert Opin Drug Deliv; 2016 Aug; 13(8):1083-91. PubMed ID: 27105838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drugs and New Posterior Delivery Methods in CME.
    de Oliveira Dias JR; Nunes RP; Goldhardt R
    Curr Ophthalmol Rep; 2017 Jun; 5(2):160-168. PubMed ID: 29062594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal steroids in the management of macular oedema.
    Sivaprasad S; McCluskey P; Lightman S
    Acta Ophthalmol Scand; 2006 Dec; 84(6):722-33. PubMed ID: 17083528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in corticosteroid therapy for uveitis.
    Taylor SR; Isa H; Joshi L; Lightman S
    Ophthalmologica; 2010; 224 Suppl 1():46-53. PubMed ID: 20714181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of intraocular corticosteroids.
    Kiernan DF; Mieler WF
    Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal steroids for macular edema: the past, the present, and the future.
    Cunningham MA; Edelman JL; Kaushal S
    Surv Ophthalmol; 2008; 53(2):139-49. PubMed ID: 18348879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluocinolone acetonide for the treatment of diabetic macular edema.
    Haritoglou C; Mayer W; Wolf A
    Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery options for the treatment of ocular inflammation.
    Lobo AM; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2010; 25(5-6):283-8. PubMed ID: 21091013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
    Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
    Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review and update of intraocular therapy in noninfectious uveitis.
    Sallam A; Taylor SR; Lightman S
    Curr Opin Ophthalmol; 2011 Nov; 22(6):517-22. PubMed ID: 21897242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion.
    Ozkok A; Saleh OA; Sigford DK; Heroman JW; Schaal S
    Retina; 2015 Jul; 35(7):1393-400. PubMed ID: 25748280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital].
    Bernard Y; Bonnin N; Farguette F; Chiambaretta F
    J Fr Ophtalmol; 2016 Jan; 39(1):1-4. PubMed ID: 26616298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in sustained-release drug delivery system for treatment of posterior segment eye diseases].
    Sun SM; Cheng LY
    Zhonghua Yan Ke Za Zhi; 2013 Sep; 49(9):847-50. PubMed ID: 24330936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
    Soubrane G; Behar-Cohen F
    J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
    Bakri SJ; Omar AF
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.